Join us now for the CBD Consumer Experience Program

Join us now for the CBD Consumer Experience Program

FDA has pressing questions about safety and efficacy of CBD when used by specific populations and for specific purposes.

In a recent post from the FDA, Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner, stated “Science forms the basis for decisions at the U.S. Food and Drug Administration (FDA) and is paramount when it comes to making decisions that will impact the health and safety of the American public. We apply this rigorous, science-based approach to matters large and small that come before the Agency — including with respect to products containing cannabis or cannabis-derived compounds, including cannabidiol (CBD). We recognize that there is significant public interest in these products, for therapeutic purposes and otherwise. At the same time, there are many unanswered questions about the science, safety, and quality of many of these products. As we approach these questions, we do so as a science-based regulatory agency committed to our mission of protecting and promoting public health.” (Click here for the full article.)

ValidCare wants to bring together the cannabis-derived product industry and meet the FDA’s need for more information about CBD. Toward this goal, we are going to open our consumer experience platform for 60 days to collect the detailed, Real World Evidence (RWE) that answers FDA’s most pressing questions. Help build the insights to under the CBD consumer experience.

Use CBD+me to track CBD Consumer ExperienceCannaconsumers – you can participate by downloading the app and sharing your experiences with cannabis-derived products. Go to to learn more.

Cannabusinesses – We invite you to join the National Consumer Experience Program. Offer this program to your consumers, who can actively participate by downloading a free app and tracking CBD experiences. Your canna-based product manufacturing organization will have access to RWE related to your products and consumers from September 1 through October 31, 2019. RWE submitted by consumers will be shared with FDA while protecting company specific IP and consumer identities.

Please join us in validating CBD’s effects and ensuring FDA has the data it needs to properly regulate hemp derived CBD.  Help the industry build the data to understand the CBD consumer experience. Call for more information – 844-825-4322.